Pfizer Became the Leader of Genetic Therapies by Acquiring Bamboo Therapeutics
Origin:Boao Forum for Asia      Time:2016-08-12 16:56:09     Views:160563

Through this acquisition, Pfizer combined the genetic therapy product series, advanced carrier design, technology and capacity of Bamboo Therapeutics with its own global scale, R&D and business experience. 
Today Pfizer (NYSE:PFE) announced its acquisition of Bamboo Therapeutics. Bamboo Therapeutics is a privately held biotechnology company based in Chapel Hill, N.C. It is focused on developing gene therapies for the potential treatment of patients with certain rare diseases related to neuromuscular conditions and those affecting the central nervous system. 

Mikael Dolsten, President of Pfizer Worldwide Research & Development, said: “We believe that gene therapy may hold the promise of bringing true disease modification for patients suffering from catastrophic diseases, and we hope to see this promise come to fruition.

Copyright@2001-2013 BFA All Rights Reserved

Technical Support: Cofortune Information Technology Co., Ltd

京公网安备 11010502034126号 琼ICP备17004813号